Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report

MASSOBRI, Laura, et al.
Treatment with apixaban in a patient with recent chronic subdural haematoma: a case report

Laura Massobrio\textsuperscript{a}, Gian Marco Rosa\textsuperscript{b}, Fabrizio Montecucco\textsuperscript{b,c}, Alberto Valbusa\textsuperscript{d}

\textsuperscript{a} Clinic of Cardiovascular Disease, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy
\textsuperscript{b} Division of Cardiology, Department of Internal Medicine, Foundation for Medical researches, University of Geneva, Switzerland
\textsuperscript{c} First Medical Clinic, Laboratory of Phagocyte Physiopathology and Inflammation, Department of Internal Medicine, University of Genoa, Italy
\textsuperscript{d} Division of Cardiology, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy

We report the case of a 79-year-old Caucasian woman with a medical history of paroxysmal-permanent non-valvular atrial fibrillation (FANV), hypertension, previous stroke and heart failure, who developed, during anticoagulant treatment with warfarin, a chronic subdural haematoma (cSDH) of the left cerebral hemisphere. She was admitted to another hospital where she underwent a craniotomy for evacuation of the cSDH. At discharge, the low-molecular-weight heparin (LMWH) enoxaparin was prescribed owing to recent neurosurgical intervention and to balance the high thromboembolic risk (CHADS2VASc score 8) with the risk of bleeding (HASBLED 4). This therapy was discontinued thirty days later because of the onset of an allergic skin reaction. Considering the safety profile of apixaban (2.5 mg b.i.d) \cite{1, 2} in patients at high risk of bleeding and of thromboembolic events (creatinine >1.5 mg/dl, age >80 years old, weight <60 kg), the patient was treated with this drug 12 hours after the last enoxaparin dose. Other LMWH or fondaparinux were previously tested but not tolerated. No major bleeding complications or other side effects were observed. The patient was admitted to our department thirty days later because of heart failure due to atrial fibrillation with rapid ventricular response (120

Figure 1
Representative CT scan image of a left fronto-temporo-parieto-occipital cSDH, before surgery (A) and after three month-follow up during apixaban treatment (B).
ment of OAC because of either the increased risk of thromboembolic complications (due to a prolonged discontinuation) or of the bleeding risk (due to early reintroduction) [3]. Generally patients such as the one described in our case report are excluded from clinical trials to determine more complex clinical management.

Considering the safety profile of apixaban 2.5 mg b.i.d in patients with a high risk of bleeding [1, 2], we prescribed this dosage to our patient in order to reduce bleeding risk and to prevent thromboembolic events. Usually, adequate anticoagulation therapy with warfarin for three weeks before cardioversion is recommended [4]. In a post-hoc retrospective subgroup analysis from the ARISTOTLE trial, it was shown that stroke or systemic embolism rates after electrical cardioversion were comparable with apixaban and warfarin. In this trial, a total of 743 cardioversions were performed in 540 patients: Importantly, 75% of the cardioversions occurred in one year [5]. However, this study presented some important limitations, such as the number of patients; it was underpowered to draw meaningful conclusions [5]. In our case electrical cardioversion was performed earlier, after only 30 days of apixaban pre-treatment, so we might speculate as a hypothesis requiring additional pathophysiological argumentation, that the more rapid use of effective anticoagulants may shorten the pre-treatment time before cardioversion. More data are necessary to test apixaban safety and efficacy in this setting. It is known that 12%–45% of patients undergoing device implantation are on OAC [6] and perioperative management of these subjects may be considered a common clinical problem. Interrupting OAC might promote thromboembolic events and maintenance of therapeutic OAC may increase the risk of bleeding. Although uninterrupted OAC therapy with warfarin appears to be safe, recent reports have also shown that heparin bridging therapy is often associated with bleeding events [6, 7]. Therefore, there is an interest in taking advantage of the newer and shorter-acting oral anticoagulants around the time of catheter ablation for AF and devices implantation. To our knowledge there are no available data about the peri-interventional use of FXa inhibitors, such as apixaban [8].

In conclusion, our report over the observation period of 210 days showed that apixaban (2.5 mg b.i.d) might be safe and effective in the context of a recent cSDH, electric cardioversion of FANV, cardiac ablation and pacemaker implantation procedures. Additional studies, including case series, are needed to support any findings from this case report.

Key words: Apixaban; chronic subdural haematoma; cardiac ablation

Funding / potential competing interests: No financial support and no other potential conflict of interest relevant to this article was reported.

Correspondence: Fabrizio Montecucco, MD, PhD, Cardiology Division, Foundation for Medical Researches, University of Geneva, CH-1211 Geneva, Switzerland, fabrizio.montecucco[at]unige.ch

References

Figure 1

Representative CT scan image of a left fronto-temporo-parieto-occipital cSDH, before surgery (A) and after three month-follow-up during apixaban treatment (B).